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Background/aim: The aim of this study was to demonstrate the validity and reliability of the Turkish version of the Michigan Neuropathy
Screening Instrument (MNSI-TR).
Materials and methods: The study included 127 patients aged 45–76 years who were previously diagnosed with type 1 or 2 diabetes.
Stability of the instrument was assessed by intraclass correlation coefficient. Reliability of the MNSI-TR was assessed using the Kuder–
Richardson formula 20 test, item-total correlations, and floor/ceiling effect. Validity was evaluated with receiver operating characteristic
curve analysis. A logistic regression model was used to determine to what degree the MNSI-TR explain nerve conduction study (NCS)
results in the prediction of neuropathy.
Results: With a cut-off value of 3.5 for the questionnaire, sensitivity and specificity of the MNSI-TR were 75.5% and 68.1%, respectively.
A cut-off of 2.75 for the physical assessment part of the scale resulted in 87.5% sensitivity and 93.6% specificity. The scale was able to
diagnose neuropathy in the rate of 71.5% of the patients diagnosed with neuropathy by NCS.
Conclusion: The MNSI-TR is a valid and reliable method for evaluating diabetic peripheral neuropathy in Turkish speaking societies.
It must be obtained a minimum of 4 points from the questionnaire part and a minimum of 2.5 points from the physical assessment part
for the diagnosis of neuropathy
Key words: Michigan, diabetic neuropathy, diabetes mellitus, reproducibility of results

1. Introduction
World Health Organization data indicate that diabetes
mellitus (DM) is one of the fastest growing health problems
worldwide and has several complications that threaten
human health [1]. Peripheral neuropathy is a common
complication of DM, affecting nearly 60% of diabetes
patients worldwide [2].
Sensory symptoms such as pain, burning, pinching,
tingling, and numbness are common in diabetic peripheral
neuropathy [3–5]. Other important clinical signs seen
in people with neuropathy are loss of vibration sense,
decreased touch, and proprioceptive sensation in the
lower extremities, disappearance of the ankle reflex, and
foot deformities, ulcerations, and amputations [2,6,7].
Therefore, early diagnosis is vital for preventing the
progression of diabetic neuropathy [5].

Nerve conduction studies are considered the gold
standard for neuropathy diagnosis but results are usually
normal in pure small fiber neuropathy if the thick fibers
are not affected. Another alternative is skin biopsy.
However, it is not usually the first choice for neuropathy
due to the difficulties in performing and interpreting the
results [8–12]. Therefore, electrophysiological testing is
considered the preferred technique [13].
Feldman et al. developed the Michigan Neuropathy
Screening Instrument (MNSI) to facilitate the detection
of neuropathy [14]. This low-cost and rapid tool was
validated in numerous studies analyzing its reliability
and precision [14–17]. The MNSI has two sections:
section A consists of 15 self-administered questions
about neuropathic symptoms, while section B includes
a lower-extremity examination and assessment of

* Correspondence: duygu-aktar@hotmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.

789

AKTAR REYHANİOĞLU et al. / Turk J Med Sci
vibration sense, ulceration, and ankle reflexes conducted
by a clinician [14].
The MNSI has been adapted into many languages
such as Portuguese and Brazilian Portuguese [18,19]. A
valid and reliable Turkish version of the MNSI will help
standardize the assessment of neuropathic patients in
Turkey. Therefore, we conducted this study to determine
the validity and reliability of the Turkish version of the
MNSI (MNSI-TR).
2. Materials and methods
This study was conducted in collaboration by the
departments of neurology, endocrinology, and physical
therapy and rehabilitation of Dokuz Eylül University
Hospital. The study was approved by the Dokuz Eylül
University ethics committee (approval no: 2018/25-27). In
accordance with the Declaration of Helsinki, all patients
provided written informed consent before the study.
The study group included patients 45 to 76 years of age
with type 1 or 2 DM according to the American Diabetes
Association (ADA) criteria [20] who presented to our
hospital between August and December 2018 and were
referred for nerve conduction study (NCS). Participants
with alcoholism, chronic kidney and liver failure, history
of cerebrovascular disease, cancer, chemotherapy and/
or radiotherapy exposure, autoimmune disease, chronic
infectious diseases, drug abuse, radicular neuropathy,
and mental or physical disabilities were excluded from
the study due to the increased risk of nondiabetes-related
neuropathy. Patients who were blind or did not speak
Turkish were also excluded. Illiterate patients were asked
to administer the MNSI questionnaire with a literate
relative. Antidepressant and anticonvulsant usage were not
considered exclusion criteria. All participants underwent
examination by both a neurologist and an endocrinologist
and their history, sociodemographic data, body mass
index, education level, type and duration of diabetes, and
physical examination and laboratory findings such as
fasting blood glucose and HbA1c were recorded.
A clinical neurophysiology fellow performed nerve
conduction study for all patients. In the upper extremity,
sensory and motor potentials of the unilateral median
and ulnar nerves, for the lower extremity, unilateral
peroneal and tibial motor nerves and sural sensory nerve
were studied. In each extremity on the opposite side,
one motor and one sensory nerve potential was also
evaluated for excluding assymetric polyneuropathy and
plexopathy. Differences in amplitude, conduction velocity,
and/or F-wave latency in at least two different nerves
were required for a diagnosis of peripheral neuropathy.
In addition to neurological examination findings,
abnormality of amplytude, conduction velocity reduction
and/or F-wave latency prolongation that is symmetric,
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length dependent and could not reach the demyelinating
range was considered as distal symmetric neuropathy [21].
The physical examination part of the instrument was
implemented by a physiotherapist with master’s degree
who had no idea about the existence of neuropathy.
2.1. Application of the Michigan Neuropathy Screening
Instrument
The MNSI has two sections, a history questionnaire
completed by the patient (section A) and a physical
assessment conducted by a medical professional (section B).
Section A assesses clinical symptoms via 15 yes/no
questions. All questions except 7 and 13 are scored as 1
point if answered ‘yes’; questions 7 and 13 are scored as
1 point if answered ‘no’. Question 15 is evaluated by the
clinician. Because question 4 can relate to impaired
circulation and question 10 to general asthenia, neither
was included in the original MNSI scoring [14]. A cut-off
point of 7 for section A was initially accepted as abnormal;
however, later studies showed that adjusting the cut-off
point to 4 improved the performance of the MNSI [17].
Section B involves a clinical assessment of the feet
including examination for dry skin, calluses, infections,
fissures, and ulcers, followed by evaluation of ankle reflexes
and vibration perception. Each foot with a deformity
counts as 1 point and each foot with an ulcer also counts
as 1 point. Ankle reflex is scored as 0 if present, 0.5 points
if present only when the patient performs Jendrassik
maneuver, and 1 point if absent despite the Jendrassik
maneuver. Vibration perception is assessed using a 128Hz tuning fork at the distal interphalangeal joint of the
participants’ great toe. The score is determined based
on how much longer the examiner can feel the vibration
than the patient. If the examiner feels the vibration for
10 or more seconds longer than the patient, vibration
sense is considered decreased and scored as 0.5 points. If
the examiner feels the vibration for less than 10 s longer,
vibration sense is considered normal (0 points). If the
patient cannot sense the vibration at all, they receive 1
point. The maximum possible score from section B is 8
points, and a score greater than 2 is considered abnormal
according to the original scoring algorithm [14].
2.2. Translation and cross-cultural adaptation
Prior to the study, we obtained permission from Dr. Eva
Feldman (first author of the original MNSI) to adapt the
instrument to Turkish. Translation and cross-cultural
adaptation of the MNSI were conducted as recommended
by Bouton et al. [22].
First, two bilingual translators (native Turkish with
English as a second language) independently translated the
original version of the MNSI from English to Turkish. The
original MNSI was compared independently with both of
the translations and a common translation was prepared
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based on feedback from specialists. Finally, two native
English-speaking translators with Turkish as a second
language and no knowledge of the original MNSI backtranslated the instrument from Turkish to English. The
translators and health professionals agreed on a revised
Turkish version, which was pretested with 19 patients.
The participants provided feedback and any mismatches
between the original and Turkish version were identified
and reviewed.
The adaptation process concluded by presenting all
documents to the language expert and content validity
committee, and the most plausible translation was
obtained.
2.3. Content validity
A team of seven experts evaluated the Turkish version
of the instrument. The team compared the original and
translated versions and scored the appropriateness of
each item between 1 and 4 points (1 = requires substantial
editing, 2 = requires minor editing, 3 = good, 4 = excellent).
The items were changed based on these recommendations.
Content validity indexes were calculated for both item-level
(I-CVI) and scale-level (S-CVI). The number of experts
who scored an item either 3 or 4 (thus dichotomizing the
ordinal scale into relevant and irrelevant) was summed
and divided by the total number of experts. S-CVI was
calculated by dividing the sum of the I-CVI values by the
number of items. Concordance of the expert opinions is
expected to be greater than 80% [23,24].
2.4. Sample size
Minimum sample size was calculated based on Hatcher’s
100 rule (1994), which states that the sample size must be
at least 100 people or 5 times the number of questionnaire
items (15 items × 5 = 75) [25]. We initially evaluated 170
people; however, after excluding patients because NCS
or physical assessment could not be completed or they
were lost to follow-up, the final number of evaluated
participants was 127.
2.5. Statistical analysis
Data were analyzed using SPSS for Windows version 22.0.
Descriptive statistics were analyzed using percentage,
mean, and standard deviation (SD). Test-retest reliability
analysis was conducted by paired-samples t-test and
Pearson correlation analysis. The retest was done three
weeks after the pretest with 19 participants [26]. The
desired correlation coefficient between the first and second
tests is ≥0.70 [27,28].
Internal consistency of the questionnaire was analyzed
using the Kuder–Richardson Formula 20 (KR-20)
coefficient. A KR-20 coefficient between 0.80 and 1.00
indicates excellent reliability, while a value between 0.60
and 0.80 is considered highly reliable [25,26]. Stability
of the instrument was assessed by intraclass correlation
coefficient (ICC). Pearson correlation analysis was used

to analyze the relationship between item-total and itemsubscale total scoring. It shows the similarity or invariance
of measurements obtained by ICC at the same or different
times from individuals. ICC above 0.60 is considered
a good fit. According to the literature, the correlation
coefficient between item-total score and item-subscale
total score should be at least 0.20 and floor and ceiling
effects should be under 0.15 to consider an instrument
homogeneous [27].
Determining floor and ceiling effects are also
recommended as an indicator of scale reliability and
validity. Minimum score obtained from the scale gives
the floor effect while the maximum score gives the ceiling
effect. If the proportion of respondents receiving floor and
ceiling scores exceeds 15%, the scale may pose a problem
both in reliability and validity [27].
Validity was assessed with receiver operating
characteristic (ROC) curve analyses. Based on the area
under the ROC curve (AUC) values, the discriminating
power of the instrument was interpreted as excellent
at AUC >0.91, very good at 0.81–0.90, acceptable at
0.71–0.80, statistically nonsignificant at 0.50–0.70, and
nondiscriminatory at <0.5 [29]. The optimal cut-off points
for the two sections of the instrument were determined
using a diagnostic index and Youden’s index, the score
corresponding to the point where these two indexes are
highest is determined as the cut-off point for that scale,
and the sensitivity and specificity values were determined
for those cut-off points [30].
Logistic regression analysis was performed to
determine the agreement between the number of patients
diagnosed with neuropathy as a result of NCS and the
number of patients diagnosed with neuropathy by scale.
3. Results
The study included 127 participants. Of these, 112 (88.2%)
had type 2 DM and 15 (11.8%) had type 1 DM. The mean
duration of diabetes was 11.42 (SD 7.47) years and the mean
age of the participants was 59.77 (SD 10.02) years. Eightytwo (64.6%) of the patients were woman and 45 (35.4%)
were men. Mean BMI was 29.11 (SD 5.07) kg/m², HbAlc
value was 7.70% (SD 1.53%), fasting blood glucose was
153.82 (SD 58.11) mg/dL. Level of education completed by
the participants was high school for 17.5%, middle school
for 28.3%, and elementary school for 42.5%, while the
remaining 11.8% of the patients were uneducated.
3.1. Content validity
Agreement between the experts ranged between 0.85 and
1 for each item (I-CVI) and was 0.95 for the entire scale
(S-CVI).
3.2. Reliability analysis for section A
Test-retest analysis of questionnaire was shown in Table
1. There was no significant difference between the first
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application score and the second application score of
the scale (P > 0.05). The correlation between the two
measurements was found to be 0.977 (Table 1).
Reliability analysis of questionnaire was shown in
Table 2. The Kuder–Richardson reliability coefficient for
Part A was found to be 0.732. The ICC was determined to
be 0.649 for section A. There was no floor or ceiling effect
for section A (Table 2). Item-total and item-subscale total
scores of correlations were 0.341–0.646 (Table 3).
3.3. Validity analysis for section A
A cut-off point of 3.5 was identified in ROC analysis
according to the diagnostic and Youden’s indexes (Figure
1) The AUC was 0.783 and sensitivity found as 75.5% while
specificity found as 68.1% for section A (Table 4).
3.4. Reliability analysis for section B
Reliability analysis results was shown in Table 2. The
Kuder–Richardson reliability coefficient for section B was
found to be 0.604. The ICC was determined to be and
there was no floor or ceiling effect for section B (Table 2).
Correlations of item-total and item-subscale scores were
between 0.372 and 0.757 (Table 5).
3.5. Validity analysis for section B
The cut-off point for section B was 2.75 (according to the
diagnostic and Youden’s indexes) and the AUC was 0.939
(Figure 2). For section B sensitivity was found as 87.5% and
specificity was 93.6% (Table 4). We detected a moderate
positive correlation between sections A and B (r = 0.519,
P = 0.00). Item-subscale total scores correlation coefficient
for Section B were between 0.372 and 0.757 (Table 5).
Logistic regression analysis was performed to
determine the agreement between the number of patients
diagnosed with neuropathy as a result of NCS and the
number of patients diagnosed with neuropathy by scale.
71.5% of the patients diagnosed neuropathy by NCS were
diagnosed neuropathy by the two sections of the MNSITR. Increasing the score of section B indicates that the
risk of neuropathy increases 5.526 fold (β = 5.526), and
increasing the score of section A indicates that the risk of
neuropathy increases 1.245 fold (β = 1.245) (Table 6).
4. Discussion
In this study, we evaluated both the validity and reliability
of a Turkish version of the MNSI. We found MNSI-TR is
a reliable and valiable form with a cut-off value of 3.5 and
sensitivity and were 75.5% and 68.1%, respectively for the
questionnaire part and for the physical assessment part
of the scale resulted sensitivity of 87.5% and specificity
of 93.6% with a cut-off value of 2.75. Additionally
neuropathy prediction ability of section B is found to be
higher than section A. Increasing the score of section B
increases the risk of neuropathy by approximately 4.4fold when compared to section A. The logistic regression
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Table 1. Test–retest analysis of the MNSI (n = 19).
n

Mean(SD)

Test

19

6.26 (2.07)

Retest

19

6.15(2.14)

z

P

r*

P

1.000

0.317

0.977

0.000

r*: correlation coefficient

model including both sections of the MNSI-TR explained
the presence of neuropathy by the rate of 71.5% accross the
nerve conduction test results in diagnosing neuropathy.
In the logistic regression analysis conducted by Herman
et al., it was found as 27% [17]. Our study shows that the
Turkish version of the MNSI was effective in the detection
of distal peripheral neuropathy.
Language validity was assessed by content validity
tests done by seven experts separately for each item and
the total scale. Our results demonstrated that I-CVI
values were between 0.85 and 1 and the S-CVI was 0.95.
Expert agreement of at least 0.80 for the scale items is
recommended [24,27]. In this study, both I-CVI and S-CVI
were over 0.80, indicating that the MNSI-TR maintains the
integrity of the original. High agreement between experts
demonstrates that the entire instrument and its individual
items were appropriate.
4.1. Reliability
The test-retest method is commonly used to evaluate the
reliability of a scale, which is assessed with test-retest
analysis. In this method, when the instrument is applied
to the same individual at different times, there should
be no difference between the measurements and the
correlation should be >0.70 for instrument stability [27].
The test-retest ICC values of the Portuguese and Brazilian
Portuguese versions of the MNSI were 0.91 and 0.864,
respectively [18,19]. In the present study, the test-retest
analysis showed no difference between the measurements
and the correlation between the two measurements was
0.97. Being high correlation between the test-retest results
of the MNSI-TR, indicating high reliability as with the
other language versions.
We also used ICC values for the participants’ responses
to evaluate the reliability of the whole instrument. The
ICC should be >0.60 and as close to 1 as possible [25,26].
The ICC value obtained in our study was greater than 0.60
for section A, indicating that the Turkish version of the
questionnaire is adequately reliable. The lower ICC value
for section B (ICC:0.439) may be explained by the fact that
it was affected by the different clinical attributes of each
patient and section B was performed by the clinician.
We evaluated the reliability of the Turkish version
of the MNSI using KR-20 coefficient, item-total score
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Table 2. Reliability analyses of the sections A and B (n = 127).
Item-subscale

Kuder–
Richardson α

ICC*

Mean (SD)

Floor effect
%

Ceiling effect
%

Section A total

0.732

0.649

4.39 (2.60)

10.2

0.0

Section B total

0.604

0.439

3.18 (1.78)

5.5

0.8

*ICC: Intraclass correlation coefficient
Table 3. Item-total scores correlation coefficient for Section A (n = 127).
Items

Item-total score
correlation (r)*

1. Are your legs and/or feet numb?

0.629*

2. Do you ever have any burning pain in your legs and/or feet?

0.570*

3. Are your feet too sensitive to touch?

0.533*

4. Do you get muscle cramps in your legs and/or feet?

0.341*

5. Do you ever have any prickling feelings in your legs or feet?

0.606*

6. Does it hurt when the bed covers touch your skin?

0.450*

7. When you get into the tub or shower, are you able to tell the hot water from the cold water?

0.004

8. Have you ever had an open sore on your foot?

0.345*

9. Has your doctor ever told you that you have diabetic neuropathy?

0.521*

10. Do you feel weak all over most of the time?

0.455*

11. Are your symptoms worse at night?

0.646*

12. Do your legs hurt when you walk?

0.504*

13. Are you able to sense your feet when you walk?

0.013

14. Is the skin on your feet so dry that it cracks open?

0.492*

15. Have you ever had an amputation?

0.122

r*: correlation coefficient

correlations, and floor/ceiling effect. A KR-20 coefficient
over 0.60 is recommended to show that the items have
integrity and the test is homogeneous [25,26]. In the
present study, KR-20 values were over 0.60 for both
sections of the MNSI-TR, indicating high reliability.
Another method for assessing reliability is the itemtotal score analysis. The correlation between the items
and total score were determined in this study. Item-total
score correlation analysis assesses the conformity of
the items to the general structure of the questionnaire,
which is analyzed separately for each item. The itemtotal score correlation should be greater than 0.20 [27,28]
and it is recommended to exclude items with correlation
coefficients less than 0.20. In our study, all items except
the 7, 13, and 15 were sufficiently correlated. Normally,
these items should have been removed from the Turkish
questionnaire due to their low correlation coefficient.
However, according to Herman et al. and the Diabetes

Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Research
Group, the sensitivities of items 7, 13, and 15 were 14.6%,
11.0%, and 4.2% and their specificities were 94.4%, 90.9%,
and 99.5%, respectively [17]. Although their sensitivity is
low, their high specificity values indicated that these items
can exclude the presence of diabetic neuropathy; thus, it
was deemed appropriate not to remove these three items
from the MNSI-TR.
In addition, questions 4 and 10 in section A were not
included in the Turkish version, similar to the original
instrument by Feldman et al. [14]. However, after
analyzing the answers to questions 4 and 10, we noted
that their correlation coefficients were greater than 0.20,
which shows a strong association with the integrity of the
instrument. In the updated version of MNSI by Herman et
al. and DCCT/EDIC, questions 4 and 10 were reintegrated
into the instrument due to their high sensitivity, especially
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Figure 1. Determination of the cut-off point for section A
according to ROC curve analysis.

question 4 [17]. Our results were also consistent with the
updated version of MNSI, although we remained loyal to
the original MNSI. However, in the future, we believe
that an updated version of the Turkish MNSI should be
studied with a much larger patient group.
Since the correlation coefficient for each item
in section B was above 0.20, it was considered to be
consistent with the general structure of the instrument.
Tables 3 and 5 show the correlations between the items
and the total score found in this analysis.
Determining floor and ceiling effects are also
recommended as an indicator of scale reliability.
Minimum score obtained from the scale gives the floor
effect while the maximum score gives the ceiling effect. If
the proportion of respondents receiving floor and ceiling
scores exceeds 15%, the scale may pose a problem both
in reliability and validity. Higher values of the floor and
ceiling effect indicate that the responses are stacked, the
homogeneous structure deteriorated, and the internal
consistency reduced [25,27]. We determined floor and

ceiling effects below 15% for both section A and B.
However, in the original study and some of the other
language adaptation studies, item-total score correlation
and ceiling/floor effect evaluations were not performed.
Briefly, our results demonstrate that both sections of
the MNSI-TR can detect the desired characteristics and
have adequate item reliability.
4.2. Validity
In ROC curve analysis, sensitivity refers to the power of
a test to identify those who are truly ill while specificity
shows the test’s ability to identify the truly healthy. For
section A of the MNSI-TR, a cut-off point of 3.5 yielded
a sensitivity of 75.5% and specificity of 68.1%. When
scoring section A of the MNSI, each item receives 0 or 1
point; therefore, because all scores were whole numbers,
we determined the minimum point as 4 for the detection
of neuropathy. In the Portuguese version, the cut-off point
for section A was found to be 3 with 100% sensitivity and
64% specificity [18]. In the original study, Feldman et al.
identified a cut-off point of 7 for section A [14]. Herman
et al. and the DCCT/EDIC Research Group observed that
the cut-off point of 7 had caused many neuropathy cases
to be overlooked; therefore, the cut-off point was updated
to 4, which had a sensitivity of 0.40 and specificity of 0.92
[17]. This cut-off point was also consistent with our study.
The cut-off point for section B of the MNSI was
determined as 2.75, which yielded a sensitivity of 87.5%
and specificity of 93.6% (Figure 2) However, as each item
in section B is worth 0.5 points, the next best minimum
point for the detection of neuropathy was 2.50. In the
Portuguese version, the cut-off point of section B was 2
with a sensitivity of 100% and a specificity of 86% [18].
Another validation study indicated a cut-off point of 2
with a sensitivity of 65 % and specificity of 83% [16]. In
a study involving an ambulatory screening of peripheral
neuropathy, the cut-off point was determined as 2.5 with
a sensitivity of 78.6% and specificity of 78.6% [15]. In the
original study, the cut-off point was 2 with a sensitivity
of 80% and a specificity of 95%, while in the updated
version (Herman et al. and DCCT/EDIC) the cut-off
point was determined as 2.5 with the 61% sensitivity and
the 97% specificity [14,17]. The cut-off point identified in

Table 4. Cut-off point, estimation values, and area under the curve (AUC) values for prediction of neuropathy
according to the ROC Analysis for sections A and B.
Cut-off
point

Sensitivity

Specificity

P

AUC*
(%95 CI)

Diagnostic
Index

Youden’s
Index

Section A

3.5

0.755

0.681

0.000

0.783

1.456

0.456

Section B

2.75

0.875

0.936

0.000

1.811

0.811

*Area under curve

794

0.939
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Table 5. Item-subscale total scores correlation coefficient for
section B.
Items

Item-total score correlation (r)

Appearance of feet

0.680*

Ulceration

0.372*

Ankle reflexes

0.757*

Vibration

0.655*

r: correlation coefficient

our study for section B of the MNSI-TR was consistent
with that of the updated version of the MNSI.
In the updated MNSI, AUC values were defined as
0.75 for section A and 0.76 for section B [17]. In the
Portuguese version, the AUC value was found as 0.913
for section A and 0.798 for section B, respectively [18].
In another study, section A was not evaluated but the
AUC of section B was 0.815 [16]. In the Turkish version,
we determined that the AUC was > 0.70 for section A,
consistent with the previous studies (Figure 1). The AUC
for section B was >0.90 (Figure 2), suggesting that section
B of the MNSI-TR has more power to differentiate
neuropathy compared to other studies.
A limitation of this study was that we included illiterate
patients. However, we assumed that 11.8% illiteracy in
our patient group would not affect the results because
both their relatives and a health professional were present
to read and explain while they took the written part of the
test (section A).
In conclusion, the MNSI-TR with cut-off values of 3.5
for section A and 2.75 for section B is a useful and reliable
method for evaluating peripheral neuropathy. However,
according to the MNSI scoring system, since each item
represents 1 point for section A and 0.5 or 1 point for

Figure 2. Determination of the cut-off point for section B
according to ROC curve analysis.

section B, accepting the minimum score as 4 points
for section A and minimum score as 2.5 for section B
confirms the presence of neuropathy. The use of MNSI-TR
is a practical and useful method for screening neuropathy
in Turkish-speaking societies.
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Table 6. Association between sections of the instrument and NCS results (Logistic regression analyses).

Variables

95% CI
B

SE

Wald

Df

Sig

Exp (B)

Lower

Upper

Section A

0.219

0.134

2.682

1

0.101

1.245

0.958

1.619

Section B

1.709

0.345

24.577

1

0.000

5.526

2.811

10.869

-2Log likelihood

73.185

Cox & Snell R Square

0.524

Nagelkerke R Square

0.715

CI: Confidence interval, B: Beta, SE: Standard Error, Df: Degree of freedom, Sig: Significance, (B): Standardized Beta
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Michigan Nöropati Tarama Sorgusu
A.Hikaye (Diyabetli kişi tarafından doldurulacaktır)
Bacaklarınız ve/veya ayaklarınız uyuşuk mu?
Hiç bacak ya da ayaklarınızda yanma tarzında ağrı hissettiniz mi?
Ayaklarınız dokunmaya karşı aşırı mı hassas?
Bacaklarınızda ve/veya ayaklarınızda kas krampı oluyor mu?
Bacaklarınızda veya ayaklarınızda hiç karıncalanma hissi oluyor mu?
Yatak örtüsü teninize temas ettiğinde canınız acıyor mu?
Banyo yaparken ya da duş alırken sıcak suyu soğuk sudan ayırabiliyor musunuz?
Ayaklarınızda hiç açık yaranız oldu mu?
Doktorunuz size hic diyabetik nöropatiniz olduğunu söyledi mi?
Çoğu zaman vücudunuzda güçsüzlük hisseder misiniz?
Belirtileriniz geceleri kötüleşiyor mu?
Yürüdüğünüz zaman bacaklarınız acıyor mu?
Yürüdüğünüz zaman ayaklarınızı hissedebiliyor musunuz?
Ayağınızın üzerindeki deriniz çatlaklar oluşacak kadar kuru mudur?
Hiç ampütasyon ameliyatı geçirdiniz mi?
Not : 15. madde klinisyen tarafından değerlendirilecektir.
Total ..................

󠆚 Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚 Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır
󠆚Evet 󠆚Hayır

B. Fiziksel Değerlendirme (Sağlık uzmanı tarafından doldurulacaktır)
1.Ayakların Görüntüsü
Sağ
a. Normal
*0 Evet *1Hayır
b. ’Hayır’ ise aşağıdakilerden uygun olanı işaretleyiniz
* Deformite
* Kuru cilt, nasır
* Enfeksiyon
* Çatlak
* Diğer
belirtiniz :.........................
2. Ülserasyon
Sağ
󠆚Yok
󠆚Var
3. Ayak bileği refleksleri
Sağ
󠆚 Var
󠆚Güçlendirerek
󠆚 Yok
4.Ayak başparmağında vibrasyon algısı
Sağ
󠆚 Var
󠆚Azalmış
󠆚 Yok

Sol
a. Normal
*0 Evet *1Hayır
b. ’Hayır’ ise aşağıdakilerden uygun olanı işaretleyiniz
* Deformite
* Kuru cilt, nasır
* Enfeksiyon
* Çatlak
* Diğer
belirtiniz :.........................
Sol
󠆚Yok

󠆚Var

Sol
󠆚Var

󠆚Güçlendirerek

Sol
󠆚Var
󠆚Azalmış
Total................

󠆚Yok
󠆚Yok

1

